Guide to writing Patent Reviews

This guide is intended to assist authors specifically in preparing Patent Reviews for submission to *Pharmaceutical Patent Analyst* and it should be consulted alongside the full author guidelines.

Contents

About *Pharmaceutical Patent Analyst* .............................................................. 2
  Journal scope.................................................................................................. 2
  Audience ........................................................................................................ 2

Patent Reviews ................................................................................................. 2
  Aim and focus................................................................................................. 2
  Scientific coverage ........................................................................................ 2
  Article structure ............................................................................................. 3

Use of tables and figures ................................................................................. 4

Published examples .......................................................................................... 4

Patent searches .................................................................................................. 5

Preparing for submission .................................................................................. 5
  Internal approval processes .......................................................................... 5
  Figure permissions ......................................................................................... 5

Submission and Editorial Policies .................................................................... 6

Editorial office contact details .......................................................................... 6

*Future Science Ltd*, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; [www.future-science.com](http://www.future-science.com)

Future Science Ltd is part of the Future Science Group [www.future-science-group.com](http://www.future-science-group.com)
About *Pharmaceutical Patent Analyst*

**Journal scope**

*Pharmaceutical Patent Analyst* is dedicated to making the essential content of key patents available in a concise and enriched format to researchers and other specialists, while also providing timely commentary on important issues related to patent and IP law. The journal’s core content therefore comprises high-impact patent reviews that provide an objective and concise appraisal of selected patents in a chosen area, set within the context of the wider relevant R&D landscape. Articles exploring patenting trends as well as those examining new methodologies for searching the patent literature also feature.

**Audience**

The journal is principally targeted at researchers and scientists who need to remain abreast of developments in the patent literature, while additionally enhancing their understanding of associated IP issues. In addition, the journal will appeal to those outside the research community, notably IP specialists, legal professionals and technology-transfer officers.

**Patent Reviews**

**Aim and focus**

Patent Reviews should provide an objective and concise appraisal of a selection of patents in a chosen area. Discussions should be placed within the context of the relevant wider R&D landscape. Authors are expected to offer a commentary on the significance, potential and essential content of the patents under discussion.

The patents reviewed should be from a variety of companies/assignees, and should be timely (*i.e.* ideally published or granted within the past 4 years; authors should indicate in their manuscript if patents have been published but not yet granted). The majority of the references cited in the article should be taken from the patent literature.

**Scientific coverage**

Patent Reviews discussing trends and developments in the patent literature covering the following areas will be considered:

- Chemical and biological entities of therapeutic significance
- Healthcare products (*e.g.*, medical devices and drug-delivery systems)
- Drug-discovery and design technologies
- Inventions in related disciplines (*e.g.*, biotechnology and nanotechnology)

Proposals for other topics can be sent to the Editor for consideration.
Article structure

*Future Science* articles have been engineered specifically for the print and online environments. The structure is designed to draw time-constrained readers directly to the information they require.

Patent Reviews should be within a 4,000—10,000-word limit (excluding Abstract, Executive Summary, References and Figure/Table legends); articles exceeding this upper limit can be accepted at the discretion of the Editor.

Authors are free to structure the main body of their Patent Review as they desire. However, all articles should include the following sections:

- **Abstract:** to include the following details:
  - The context and purpose of the paper;
  - A succinct summary of the main findings or themes (authors are encouraged, where possible, to indicate the criteria employed to select the patents under review);
  - A brief conclusion of what the reader should learn from the paper and what its implications might be.
- **Introduction/Background:** brief summary of the underlying science; readers should be directed to appropriate references for more in-depth coverage.
- **Body of article:** objective commentary and analysis of chosen patents, set within the context of the relevant wider R&D landscape; authors are free to structure this section as they choose.
- **Future perspective:** speculative viewpoint on how the field will evolve in 5–10 years time.
- **Executive summary:** bulleted summary points that illustrate the main topics or conclusions made under each of the main headings of the article.
- **References:** the majority of which should be patents.
- **Reference annotations:** 6–8 references that are of particular significance to the subject accompanied by a brief (1–2 line) synopsis.
- **Financial disclosure/Acknowledgements**

More detailed information on each of these sections can be found in the journal’s author guidelines.
Use of tables and figures

Authors are encouraged to include tables or figures to assist readers. Examples from published Patent Reviews are given below.

### Table 1. Some patented authentic HIV-1 integrase inhibitors and their biological activities.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Assignee</th>
<th>Patent number</th>
<th>IC_{50} (ST, μM)</th>
<th>EC_{50} (μM)</th>
<th>EC_{50} (μM)</th>
<th>CC_{50} (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Shionogi &amp; Co., Ltd</td>
<td>WO 9950245 A1</td>
<td>0.07</td>
<td>1.5</td>
<td>9.6</td>
<td>520</td>
</tr>
<tr>
<td>2</td>
<td>Merck &amp; Co., Inc.</td>
<td>WO 9962513 A1</td>
<td>0.133</td>
<td>1.2</td>
<td>17.7</td>
<td>88.3</td>
</tr>
<tr>
<td>3</td>
<td>Merck &amp; Co., Inc.</td>
<td>WO 9962520 A1</td>
<td>0.30</td>
<td>1.0</td>
<td>1.053</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Merck &amp; Co., Inc.</td>
<td>WO 9962520 A1</td>
<td>&lt;0.10</td>
<td>0.20</td>
<td>5.9</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Bristol-Myers Squibb</td>
<td>WO 200196283 A2</td>
<td>0.20</td>
<td>0.20</td>
<td>5.9</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Bristol-Myers Squibb</td>
<td>WO 2003049680 A2</td>
<td>99.9% inhibition</td>
<td>99.9% inhibition</td>
<td>at 50 μM</td>
<td>50 μM</td>
</tr>
</tbody>
</table>

Table 1. Some patented authentic HIV-1 integrase inhibitors and their biological activities.

Figure 3. Representative diketo acids and diketo acid analogues patented as HIV-1 integrase inhibitors.

Published examples

A selection of previously published examples is below; a sample article is available upon request.


Patent searches

There are numerous databases available that allow users to conduct patent searches. The following is a selection of free-to-access services; this list is not exhaustive.

If you identify any other patent-searching resources that you find particularly useful, we would be interested to hear about them.

- European Patent Office
- United States Patent and Trademark Office (not the most user friendly site)
- The World Intellectual Property Organization’s Patent Scope
- Espacenet
- Patent Lens
  [http://www.patentlens.net/daisy/patentlens/patentlens.html](http://www.patentlens.net/daisy/patentlens/patentlens.html)
- Priorsmart
- PriorIP

Preparing for submission

Internal approval processes

To prevent delays, authors are advised to obtain any necessary internal approval for their proposed submission from their organization/institution as soon as is feasibly possible in advance of the submission deadline agreed with the Editor. In the event of any likely delays, authors are asked to inform the Editor.

Figure permissions

It is the responsibility of the author to obtain permission to reproduce any previously published material, and to cover any costs this incurs. As it can be time-consuming to obtain permissions, it is recommended that this process is begun early. *Future Science* is a signatory of the STM permissions copyright agreement, which facilitates the re-use of limited amounts of material from published works of other signatories. Links to most of the major journals’ permission request forms can be found at this [web page](http://www.future-science.com).
Submission and Editorial Policies

Please see here for full details regarding pre-submission editing services, instructions on how to submit your article to the journal, and full details of our journal policies.

Editorial office contact details

If you have any queries regarding the drafting of your manuscript, the submission or publication processes, or would like to find out more about other Future Science titles, please contact the Editor.